These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23928148)

  • 1. Evaluation of pluronic nanosuspensions loading a novel insoluble anticancer drug both in vitro and in vivo.
    Tang XJ; Fu YH; Meng QH; Li LM; Ying XY; Han M; He QJ; Yang B; Zeng S; Hu YZ; Sheng XX; Gao JQ
    Int J Pharm; 2013 Nov; 456(1):243-50. PubMed ID: 23928148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of PIK-75 nanosuspension formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-cancer therapy.
    Talekar M; Ganta S; Amiji M; Jamieson S; Kendall J; Denny WA; Garg S
    Int J Pharm; 2013 Jun; 450(1-2):278-89. PubMed ID: 23632263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanosuspensions as delivery system for gambogenic acid: characterization and in vitro/in vivo evaluation.
    Yuan H; Li X; Zhang C; Pan W; Liang Y; Chen Y; Chen W; Liu L; Wang X
    Drug Deliv; 2016 Oct; 23(8):2772-2779. PubMed ID: 26292058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
    Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
    Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The multilayer nanoparticles formed by layer by layer approach for cancer-targeting therapy.
    Oh KS; Lee H; Kim JY; Koo EJ; Lee EH; Park JH; Kim SY; Kim K; Kwon IC; Yuk SH
    J Control Release; 2013 Jan; 165(1):9-15. PubMed ID: 23103984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and characterization of intravenously injectable curcumin nanosuspension.
    Gao Y; Li Z; Sun M; Guo C; Yu A; Xi Y; Cui J; Lou H; Zhai G
    Drug Deliv; 2011 Feb; 18(2):131-42. PubMed ID: 20939679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glabridin nanosuspension for enhanced skin penetration: formulation optimization, in vitro and in vivo evaluation.
    Wang WP; Hul J; Sui H; Zhao YS; Feng J; Liu C
    Pharmazie; 2016 May; 71(5):252-7. PubMed ID: 27348968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation and comparative evaluation of HPMC and water soluble chitosan-based sparfloxacin nanosuspension for ophthalmic delivery.
    Ambhore NP; Dandagi PM; Gadad AP
    Drug Deliv Transl Res; 2016 Feb; 6(1):48-56. PubMed ID: 26545605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanocarrier improves the bioavailability, stability and antitumor activity of camptothecin.
    Tang XJ; Han M; Yang B; Shen YQ; He ZG; Xu DH; Gao JQ
    Int J Pharm; 2014 Dec; 477(1-2):536-45. PubMed ID: 25445532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.
    Gao L; Zhang D; Chen M; Duan C; Dai W; Jia L; Zhao W
    Int J Pharm; 2008 May; 355(1-2):321-7. PubMed ID: 18242896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension.
    Wang Y; Liu Z; Zhang D; Gao X; Zhang X; Duan C; Jia L; Feng F; Huang Y; Shen Y; Zhang Q
    Colloids Surf B Biointerfaces; 2011 Apr; 83(2):189-97. PubMed ID: 21176876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanosuspension for the delivery of a poorly soluble anti-cancer kinase inhibitor.
    Danhier F; Ucakar B; Vanderhaegen ML; Brewster ME; Arien T; Préat V
    Eur J Pharm Biopharm; 2014 Sep; 88(1):252-60. PubMed ID: 24859391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction.
    Xiong XY; Guo L; Gong YC; Li ZL; Li YP; Liu ZY; Zhou M
    Eur J Pharm Sci; 2012 Aug; 46(5):537-44. PubMed ID: 22538053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery.
    Ganta S; Paxton JW; Baguley BC; Garg S
    Int J Pharm; 2009 Feb; 367(1-2):179-86. PubMed ID: 18848873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and in vitro-in vivo evaluation of teniposide nanosuspensions.
    He S; Yang H; Zhang R; Li Y; Duan L
    Int J Pharm; 2015 Jan; 478(1):131-137. PubMed ID: 25448575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
    Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
    Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a crystalline nanosuspension: polymorphism, process induced transformation and in vivo studies.
    Sharma P; Zujovic ZD; Bowmaker GA; Marshall AJ; Denny WA; Garg S
    Int J Pharm; 2011 Apr; 408(1-2):138-51. PubMed ID: 21272627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
    Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
    Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Particle size tailoring of ursolic acid nanosuspensions for improved anticancer activity by controlled antisolvent precipitation.
    Wang Y; Song J; Chow SF; Chow AH; Zheng Y
    Int J Pharm; 2015 Oct; 494(1):479-89. PubMed ID: 26302857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fabrication of quercetin nanocrystals: comparison of different methods.
    Kakran M; Shegokar R; Sahoo NG; Shaal LA; Li L; Müller RH
    Eur J Pharm Biopharm; 2012 Jan; 80(1):113-21. PubMed ID: 21896330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.